Using engineered exosomes to target and eliminate HBV-infected cells
Engineered exosomes carrying synthetic gRNA/Cas9 targeting HBV-infected cells
['FUNDING_R01'] · EAST TENNESSEE STATE UNIVERSITY · NIH-11075295
This study is exploring a new way to help people with chronic hepatitis B by using specially designed tiny particles that can deliver tools to directly target and remove the virus from infected liver cells, aiming to provide a safer and more effective treatment than what’s currently available.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EAST TENNESSEE STATE UNIVERSITY (nih funded) |
| Locations | 1 site (JOHNSON CITY, UNITED STATES) |
| Trial ID | NIH-11075295 on ClinicalTrials.gov |
What this research studies
This research investigates a novel approach to treat chronic hepatitis B virus (HBV) infections by using engineered exosomes that carry synthetic gRNA and Cas9 proteins. These exosomes are designed to specifically target and edit the genetic material of HBV-infected liver cells, potentially eliminating the virus from the body. The study aims to overcome the limitations of current antiviral treatments that cannot fully eradicate the virus. By utilizing a non-viral delivery system, the research seeks to minimize safety concerns associated with traditional gene-editing methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic hepatitis B virus infection who have not responded adequately to existing antiviral therapies.
Not a fit: Patients who are not infected with HBV or those who have already achieved viral clearance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a curative treatment for patients with chronic HBV infections.
How similar studies have performed: While the use of CRISPR/Cas9 technology is gaining traction, this specific approach using engineered exosomes for HBV treatment is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
JOHNSON CITY, UNITED STATES
- EAST TENNESSEE STATE UNIVERSITY — JOHNSON CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YAO, ZHI Q. — EAST TENNESSEE STATE UNIVERSITY
- Study coordinator: YAO, ZHI Q.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.